Maneesh Tandon

1.7k total citations
18 papers, 138 citations indexed

About

Maneesh Tandon is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Maneesh Tandon has authored 18 papers receiving a total of 138 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 13 papers in Pathology and Forensic Medicine and 6 papers in Oncology. Recurrent topics in Maneesh Tandon's work include Lymphoma Diagnosis and Treatment (13 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Acute Lymphoblastic Leukemia research (5 papers). Maneesh Tandon is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Acute Lymphoblastic Leukemia research (5 papers). Maneesh Tandon collaborates with scholars based in United Kingdom, United States and Germany. Maneesh Tandon's co-authors include Kirsten Fischer, Othman Al‐Sawaf, Michael Hallek, Barbara Eichhorst, Anna‐Maria Fink, Giuseppe Gritti, Sandra Robrecht, Clemens‐Martin Wendtner, Stephan Stilgenbauer and Eugen Tausch and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Hematology.

In The Last Decade

Maneesh Tandon

15 papers receiving 137 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maneesh Tandon United Kingdom	8	99	77	65	35	23	18	138
Elżbieta Iskierka‐Jazdzewska Poland	7	84 0.8×	71 0.9×	36 0.6×	26 0.7×	11 0.5×	25	110
Henriette W Berenschot Netherlands	6	126 1.3×	62 0.8×	103 1.6×	21 0.6×	9 0.4×	11	164
Joel Wight Australia	8	104 1.1×	43 0.6×	58 0.9×	15 0.4×	21 0.9×	22	157
Jesse Shustik Canada	5	114 1.2×	50 0.6×	78 1.2×	12 0.3×	16 0.7×	11	142
Austin I. Kim United States	7	129 1.3×	120 1.6×	55 0.8×	50 1.4×	29 1.3×	17	179
Ivelise Rijo United States	5	62 0.6×	38 0.5×	45 0.7×	16 0.5×	38 1.7×	7	126
Anupkumar George Australia	4	100 1.0×	54 0.7×	65 1.0×	8 0.2×	22 1.0×	6	143
Paolo Caimi United States	7	228 2.3×	65 0.8×	193 3.0×	32 0.9×	24 1.0×	9	265
Gayane Tumyan Russia	5	75 0.8×	56 0.7×	60 0.9×	22 0.6×	7 0.3×	22	117
Allison Barraclough Australia	8	106 1.1×	30 0.4×	87 1.3×	20 0.6×	21 0.9×	29	152

Countries citing papers authored by Maneesh Tandon

Since Specialization

Citations

This map shows the geographic impact of Maneesh Tandon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maneesh Tandon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maneesh Tandon more than expected).

Fields of papers citing papers by Maneesh Tandon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maneesh Tandon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maneesh Tandon. The network helps show where Maneesh Tandon may publish in the future.

Co-authorship network of co-authors of Maneesh Tandon

This figure shows the co-authorship network connecting the top 25 collaborators of Maneesh Tandon. A scholar is included among the top collaborators of Maneesh Tandon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maneesh Tandon. Maneesh Tandon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Hutchings, Martin, Anna Sureda, Francesc Bosch, et al.. (2025). Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial. Journal of Clinical Oncology. 43(36). 3788–3798.

Nijland, Marcel, Fabrice Jardin, Corinne Haïoun, et al.. (2025). 152 | GLOFITAMAB+R‐CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED LARGE B‐CELL LYMPHOMA DEFINED AS HIGH RISK BY CIRCULATING TUMOR DNA (ctDNA) DYNAMICS: PRIMARY RESULTS. Hematological Oncology. 43(S3).

Gritti, Giuseppe, Anton Belousov, James Relf, et al.. (2024). Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma. Blood Advances. 8(14). 3615–3618. 10 indexed citations

Falchi, Lorenzo, Fabrice Jardin, Corinne Haïoun, et al.. (2023). Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results. Blood. 142(Supplement 1). 858–858. 14 indexed citations

Tandon, Maneesh, et al.. (2023). Real-World Incidence, Characteristics and Management of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cell Therapy across Hematologic Malignancies. Blood. 142(Supplement 1). 5150–5150. 2 indexed citations

Samineni, Divya, Leonid Gibiansky, Bei Wang, et al.. (2022). Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial. Advances in Therapy. 39(8). 3635–3653. 7 indexed citations

Komanduri, Krishna V., Anton Belousov, Mark Dixon, James Relf, & Maneesh Tandon. (2022). Risk of Cytokine Release Syndrome with Glofitamab Is Predicted By an Updated Model with a Potential Clinical Application. Blood. 140(Supplement 1). 9493–9495. 4 indexed citations

Al‐Sawaf, Othman, Brittany Gentile, Jacob Devine, et al.. (2021). Health‐related quality of life with fixed‐duration venetoclax‐obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial. American Journal of Hematology. 96(9). 1112–1119. 8 indexed citations

Hutchings, Martin, Anna Sureda, María José Terol, et al.. (2021). Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 138(Supplement 1). 525–525. 31 indexed citations

10.

Al‐Sawaf, Othman, Sandra Robrecht, Maneesh Tandon, et al.. (2021). VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY. Hematological Oncology. 39(S2). 11 indexed citations

11.

Tausch, Eugen, Christof Schneider, Deyan Y. Yosifov, et al.. (2021). GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PLUS EITHER CHLORAMBUCIL OR VENETOCLAX ‐ UPDATED ANALYSIS OF THE CLL14 TRIAL. Hematological Oncology. 39(S2). 6 indexed citations

12.

Al‐Sawaf, Othman, Can Zhang, Maneesh Tandon, et al.. (2020). Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial.. Journal of Clinical Oncology. 38(15_suppl). 8027–8027. 5 indexed citations

13.

Al‐Sawaf, Othman, Can Zhang, Sandra Robrecht, et al.. (2020). Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial. Blood. 136(Supplement 1). 22–23. 20 indexed citations

14.

Al‐Sawaf, Othman, Anna‐Maria Fink, Sandra Robrecht, et al.. (2019). Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial. Blood. 134(Supplement_1). 4315–4315. 8 indexed citations

15.

Tausch, Eugen, Jasmin Bahlo, Sandra Robrecht, et al.. (2019). GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORABMUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY Best abstract submitted by a young investigator / travel grant recipient. Hematological Oncology. 37(S2). 84–86. 2 indexed citations

16.

Al‐Sawaf, Othman, Brittany Gentile, Jacob Devine, et al.. (2019). Rapid Improvement of Patient-Reported Outcomes with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated CLL and Coexisting Conditions: A Prospective Analysis from the CLL14 Trial. Blood. 134(Supplement_1). 4305–4305. 4 indexed citations

17.

Fischer, Kirsten, Othman Al‐Sawaf, Jasmin Bahlo, et al.. (2019). Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.. Journal of Clinical Oncology. 37(15_suppl). 7502–7502.

18.

Tausch, Eugen, Jasmin Bahlo, Sandra Robrecht, et al.. (2019). S105 GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY. HemaSphere. 3(S1). 4–4. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact